Nanocarriers (Liposomes, Polymeric NPs) can encapsulate chemotherapy agents to target canine and feline tumors, increasing drug concentration at the tumor site while mitigating dose-limiting cardiotoxicity. They also enable stable delivery of anti-inflammatory drugs for chronic conditions like arthritis.
Nanoparticle Application in Companion Animal
Are you currently facing targeted delivery challenges, rising antibiotic resistance (AMR), or issues with systemic toxicity in veterinary drug development? Our Advanced Nanocarrier Design and Formulation Platform helps you accelerate drug development and obtain high-efficacy treatments through site-specific targeting and controlled drug release technology. Nanotechnology is essential for achieving superior bioavailability and safety in complex pet disease management.
Click Here to View more about our Service
Overview of Applications of Nanoparticles in Companion Animals
The critical challenges in veterinary R&D, particularly managing chronic diseases and combating AMR, demand solutions beyond conventional pharmacology. Nanoparticles provide the unparalleled ability for site-specific targeting and enhanced therapeutic efficacy, revolutionizing the safety and quality of pet care.
What Are Our Research Areas?
The application of nanoparticles (NPs) in veterinary medicine spans diagnostics, therapeutics, and nutrition, aiming to secure sustainable food supply chains and improve animal welfare. Our core research focuses on engineering materials at the nanoscale (1-100 nm) to overcome the biological barriers encountered by traditional drugs, vaccines, and nutrients in animals, including cattle, poultry, swine, and aquaculture. This preclinical research background involves designing nanocarriers that can bypass stomach acid, penetrate cell membranes, and specifically target diseased tissues or organs, ensuring minimal off-target effects and maximum therapeutic efficacy. This includes the development of next-generation nano-vaccines with enhanced immunogenicity and feed additives that dramatically improve nutrient bioavailability and counter mycotoxin contamination.
Why Choose Us?
Nanoparticles offer distinct, competitive advantages over traditional small-molecule drugs for companion animal health:
- Targeted Delivery: Enables active or inactive targeting, accumulating therapeutics directly at the disease site (e.g., tumor, infection focus) to maximize local efficacy.
- Enhanced Bioavailability: Improves the solubility and absorption of poorly soluble drugs, allowing for effective systemic delivery at lower overall doses.
- Controlled Release: Provides sustained drug release kinetics, reducing the frequency of dosing/administration and improving pet owner compliance and animal welfare.
- AMR Circumvention: Metallic and specialized NPs offer mechanisms that directly combat bacterial and fungal pathogens, providing a critical alternative to failing conventional antibiotics.
- Reduced Systemic Toxicity: Lower effective doses and site-specific targeting significantly reduce drug exposure in healthy tissues, lowering the risk of adverse side effects in pets.
Key Applications
Creative Biolabs supports the development of products across the entire companion animal health spectrum by leveraging advanced nanocarrier technology:
Precision Oncology & Chronic Disease
Combating Antimicrobial Resistance (AMR)
Silver, Zinc Oxide, and specialized inorganic NPs provide non-antibiotic antimicrobial, antifungal, and antiviral activities. This offers effective topical or systemic solutions for resistant pet infections, including innovative formulations for sensitive areas like the eyes.
Advanced Diagnostics & Theranostics
Highly sensitive NP-based biosensors and probes enhance the detection limit of biomarkers for early disease diagnosis (infectious diseases, metabolic disorders) in bodily fluids, enabling rapid, accurate Point-of-Care (PoC) testing in veterinary clinics. The ultimate goal is theranostics—combining diagnostic detection and therapy in a single NP platform.
Prophylaxis & Hygiene
NPs function as powerful adjuvants or carriers in nanovaccines, improving immune response and potentially enabling long-term prophylactic treatments with reduced frequency of administration. Furthermore, NP-enhanced coatings and disinfectants minimize pathogen load in pet habitats, improving overall hygiene.
Fig.2 Contemporary clinical utilizations of silver nanoparticles (AgNPs) in veterinary medicine.1
Explore How We Can Support You - Schedule a Meeting!
How We Support Your Nanoparticle R&D
Creative Biolabs provides end-to-end service capabilities necessary for the successful transition of nanoparticle research to commercial veterinary products.
Conventional Liposomes Development
Anti-Infective Treatments: Ideal for initial development of encapsulated antibiotics and anti-parasitics.
Active Targeting LNP Development Precision
Precision Oncology: Essential for functionalizing LNPs with ligands to target tumor cells in companion animals.
Micelle-based Delivery System Development
Chronic Disease Management: Optimizing delivery for anti-inflammatory or pain management drugs with poor solubility.
Nucleic Acids (mRNA, siRNA)
Nanovaccine Development: Synthesis of mRNA/siRNA payloads for use in LNP-based prophylactic vaccines.
Targeting Ligand-Delivery System Conjugation
Theranostics: Covalently linking diagnostic probes or targeting peptides to NP surfaces for combined detection and therapy.
Safety & Efficacy Validation: Critical characterization to ensure batch consistency and optimize biodistribution in companion animal
Translational Impact
By partnering with Creative Biolabs, our clients gain a decisive competitive advantage in the rapidly evolving companion animal market. The adoption of nanomedicine directly translates to superior product profiles and accelerated market approval.
Nanoparticle-based treatments enable lower drug dosages while achieving equal or greater therapeutic effect, leading to a significant reduction in toxicity risk for pets. This enhanced safety profile provides a strong differentiation point in a highly competitive market and supports robust regulatory filings. Data suggests nano-formulations can increase drug bioavailability by over 50% compared to macro-formulations, leading to better clinical outcomes and high product value.
Leverage the Creative Biolabs Advantage - Request Your Quote Today!
Products
Accelerate your internal R&D pipeline with Creative Biolabs' specialized nanoparticle components and kits designed for animal health applications.
| Product Name | Description | Inquiry |
|---|---|---|
| Targeted Drug Delivery Products | Ready-to-use functionalized nanocarriers designed for enhanced accumulation in specific canine and feline disease tissues. | |
| Lipid Nanoparticle Products | High-purity, scalable LNPs optimized for the encapsulation and delivery of nucleic acid payloads (mRNA/siRNA) for veterinary vaccine research. | |
| Targeting Module Products | Custom-synthesized peptides and aptamers for the surface modification of NPs, enabling active targeting of specific cell receptors in companion animals. |
Frequently Asked Questions
How do nanoparticle products compare to traditional pet medications in terms of toxicity and side effects?
The primary advantage of nanomedicine is the ability to enable targeted delivery and controlled release. This means a lower overall dose of the therapeutic agent is needed, and the drug is concentrated at the site of disease (like a tumor). This targeted approach is designed to significantly reduce systemic drug exposure and, consequently, lower the risk of side effects compared to non-targeted conventional formulations.
Is the cost of manufacturing nanoparticle therapeutics prohibitively high for the general companion animal market?
While the initial R&D and formulation can be complex, Creative Biolabs focuses on scalable, cost-effective synthesis methods. The resulting product's enhanced efficacy, reduced dosing frequency, and superior safety profile often lead to a higher return on investment (ROI) and increased market value, making the final product competitive and highly desirable to pet owners.
Can nanoparticles be used for existing drugs that have failed due to low efficacy or poor pharmacokinetics?
Absolutely. This is a core strength of our platform—we specialize in drug rescue. By encapsulating the failing drug in a nanocarrier like a liposome or micelle, we can dramatically improve its solubility, stability, and bioavailability, often transforming a non-viable candidate into a high-performing product.
Creative Biolabs is committed to advancing the frontier of companion animal care through innovative nanomedicine. Our comprehensive services—from LNP Design & Formulation to Targeting Module Synthesis and full regulatory-compliant Characterization—provide the necessary expertise to commercialize your next groundbreaking product. To explore a partnership, discuss a specific formulation challenge, or request a detailed quote, please reach out to our specialist R&D team.
Reference
- Frippiat, Thibault, Tatiana Art, and Catherine Delguste. "Silver nanoparticles as antimicrobial agents in veterinary medicine: current applications and future perspectives." Nanomaterials 15.3 (2025): 202. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/nano15030202
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
